can i breastfeed on tirzepatide 📣 New Article Alert! Curious about and breastfeeding? 🤱 Our latest article breaks down what the current evidence says about tirzepatide transfer into breast milk. 👉 Read more here: https://infantrisk.com/content/what-breastfeeding-moms Live vaccinations and Immunosuppressant medication

Because it influences several systems simultaneously, tirzepatide requires careful patient monitoring and adherence to maximize its therapeutic effects

McGuinness LA, Higgins JPT

Obesity and Weight Management Research The primary focus of cagrilintide research has been its profound effects on body weight reduction [9] : Key Clinical Trial Data - Phase 2 ONWARDS 1 Design: 32-week, dose-ranging study in 706 adults with overweight/obesity Results (Cagrilintide monotherapy): [9] 0.3 mg weekly: -3.9% weight loss 0.6 mg weekly: -6.0% weight loss 1.2 mg weekly: -8.1% weight loss 2.4 mg weekly: -10.8% weight loss 4.5 mg weekly: -10.4% weight loss Mechanism: Weight loss attributed primarily to reduced energy intake (-535 kcal/day at 2.4 mg dose) rather than increased energy expenditure Research Implications: Cagrilintide provides a valuable research tool for investigating amylin receptor-mediated satiety pathways independent of GLP-1 signaling, offering insights into hormone-specific contributions to appetite regulation

When B12 levels drop, it can lead to fatigue, cognitive difficulties, mood imbalances, nerve problems, and even anemia